RT Journal Article
SR Electronic
T1 A model of endemic coronavirus infections
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.08.20227975
DO 10.1101/2020.11.08.20227975
A1 Huen, David S.
YR 2020
UL http://medrxiv.org/content/early/2020/11/12/2020.11.08.20227975.abstract
AB This work proposes that epidemiological features of both endemic coronaviruses and the recent highly pathogenic outbreak coronaviruses can be combined within an integrated framework. In this framework, mortality amongst those infected for the first time is mostly amongst the old but survivors acquire fatal infection immunity (FII). Subjects with FII can subsequently be infected and infect others without suffering significant mortality. Under these conditions, coronaviruses induce endemic infections that elicit FII in individuals during childhood when the risk of mortality is low and maintain it throughout their lifetime, thereby protecting the population against the worst effects of infection.A multi-compartment ODE model was constructed to explore the implications of this proposal on the evolution of a zoonosis sharing properties of both SARS-CoV-2 and endemic coronaviruses. The results show that mortality has two components, the first incurred during transition to endemicity and the other is exacted on a continuing basis. The relative contribution of each depends on the longevity of the FII state. In particular, a one-time vaccination of the older subpopulation is sufficient to reduce total mortality if FII is long-lived. The effect of a regular vaccination was also examined when FII was shorter lived. Herd immunity was not achieved.The validity of this proposal with regard to Covid-19 depends on whether reinfection with SARS-CoV-2 behaves in the manner expected of FII. If it does, then certain considerations apply to how Covid-19 is to be managed and how vaccine choice could influence that.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was entirely self-funded.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not Applicable.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data and code used to generate this manuscript are deposited in supplementary material.